News & Perspective

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Oct 29, 2007

Oct 29, 2007

THE PANDEMIC VACCINE PUZZLE Part 3: H5N1 poses major immunologic challenges

Editor's note: This is the third in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Oct 25, 2007

Oct 25, 2007

THE PANDEMIC VACCINE PUZZLE Bibliography

Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Aug 16, 2007

Aug 16, 2007

Glaxo sells more H5N1 vaccine to US, launches trial

(CIDRAP News) – The British pharmaceutical company GlaxoSmithKline (GSK) recently announced another major order of prepandemic H5N1 influenza vaccine from the US Department of Health and Human Services (HHS), along with plans to launch a North American clinical trial of the vaccine.

Jun 04, 2007

Jun 04, 2007

FDA issues guidance on flu vaccine development

(CIDRAP News) – The US Food and Drug Administration recently released separate documents outlining the kinds of clinical data required for licensing of new seasonal and pandemic influenza vaccines.

In a May 31 news release, the agency said the guidance documents were designed to facilitate the rapid development and approval of new vaccines by outlining the regulatory pathways for companies.

May 30, 2007

May 30, 2007

Baxter denies report of vaccine trial in Indonesia

(CIDRAP News) – Indonesia's health minister said yesterday that Baxter Healthcare Corp would launch a clinical trial of an H5N1 avian influenza vaccine in Indonesia in July, according to news reports, but a Baxter official said the company has not announced any clinical trials.

May 09, 2007

May 09, 2007

EU approves Novartis's 'mock-up' pandemic vaccine

(CIDRAP News) – The European Union (EU) this week approved a "mock-up" influenza vaccine made by Novartis to permit a faster start on vaccine production in the event of a flu pandemic.

Apr 24, 2007

Apr 24, 2007

Six countries to get grants for flu vaccine production

(CIDRAP News) – In an effort to improve developing countries' access to potential pandemic influenza vaccines, the WHO (World Health Organization) said today it is awarding grants to six countries to help them develop the capacity to make flu vaccine.

Apr 06, 2007

Apr 06, 2007

Cambodia, Egypt report H5N1 cases; Indonesia demands vaccine

(CIDRAP News) – New human cases of H5N1 avian influenza were reported in Cambodia and Egypt today, while Indonesian officials, according to one news service, said they would not resume sharing H5N1 virus samples unless vaccine manufacturers promise to provide the country with free pandemic flu vaccines.

Mar 06, 2007

Mar 06, 2007

Glaxo H5N1 vaccine may work against multiple strains

Editor's note: This story was revised Mar 7 to clarify information about global influenza vaccine production capacity.

Pages

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»